Lipopolysaccharides, from E. coli O55:B5
Based on 510 publication(s) in Google Scholar
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be widely used to induce cellular inflammation and establish animal models related to inflammation.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
For research use only. We do not sell to patients.
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Lipopolysaccharides, from E. coli O55:B5
More- Cell. 2025 Sep 18;188(19):5403-5425.e33. [Abstract]
- Cell. 2025 Aug 21;188(17):4586-4603.e31. [Abstract]
- Imeta. 2025 Feb 23;4(2):e70005. [Abstract]
- Cell Metab. 2026 Feb 3;38(2):370-387.e10. [Abstract]
- Adv Mater. 2024 May;36(19):e2311964. [Abstract]
- Adv Mater. 2023 Mar;35(12):e2210787. [Abstract]
- Immunity. 2024 Mar 12;57(3):495-512.e11. [Abstract]
- Cell Res. 2023 Dec;33(12):904-922. [Abstract]
- Exploration. 2025 Dec 18;5(6):20240396. [Abstract]
- Exploration (Beijing). 2025 Oct 31;5(6):20240062. [Abstract]
- Sci Bull. 2025 Nov 25:S2095-9273(25)01198-3. [Abstract]
- Bioact Mater. 2024 Sep 4:42:270-283. [Abstract]
- Bioact Mater. 2024 Jul 23:41:221-238. [Abstract]
- Nat Cell Biol. 2026 Apr;28(4):812-827. [Abstract]
- Adv Funct Mater. 2025 Nov 17.
- Adv Funct Mater. 10 March 2022.
- ACS Nano. 2025 Oct 21;19(41):36813-36825. [Abstract]
- ACS Nano. 2024 Aug 13;18(32):21009-21023. [Abstract]
- ACS Nano. 2024 Jan 30;18(4):3053-3072. [Abstract]
- Nat Commun. 2026 Jan 27;17(1):2061. [Abstract]
- Nat Commun. 2025 Aug 18;16(1):7672. [Abstract]
- Nat Commun. 2025 Apr 28;16(1):3975. [Abstract]
- Nat Commun. 2025 Mar 4;16(1):2175. [Abstract]
- Cell Death Differ. 2026 Mar 11. [Abstract]
- Bone Res. 2026 Mar 10;14(1):29. [Abstract]
- Adv Sci (Weinh). 2026 Mar 13:e17450. [Abstract]
- Adv Sci (Weinh). 2026 Mar 31:e02791. [Abstract]
- Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]
- Adv Sci (Weinh). 2025 Oct 27:e13775. [Abstract]
- Adv Sci (Weinh). 2025 Aug 11:e04896. [Abstract]
- Adv Sci (Weinh). 2024 Nov 19:e2407222. [Abstract]
- Adv Sci (Weinh). 2024 Oct 25:e2410769. [Abstract]
- Adv Sci (Weinh). 2023 Nov;10(32):e2303349. [Abstract]
- Adv Sci (Weinh). 2022 Jul;9(21):e2105650. [Abstract]
- Theranostics. 2025 May 30;15(13):6553-6571. [Abstract]
- Theranostics. 2023 Feb 21; 13(4): 1381-1400. [Abstract]
- Theranostics. 2022 Jul 4;12(11):5220-5236. [Abstract]
- Chem Eng J. 2026 Jan 7;529:172480.
- Chem Eng J. 2024 Sep 20.
- Chem Eng J. 2024 Feb 16, 149761.
- J Adv Res. 2026 Feb 11:S2090-1232(26)00141-4. [Abstract]
- Biomaterials. 2026 Sep:332:124156. [Abstract]
- Biomaterials. 2025 Dec 1:328:123882. [Abstract]
- Biomaterials. 2024 Mar:305:122466. [Abstract]
- J Exp Clin Cancer Res. 2024 Jun 26;43(1):177. [Abstract]
- J Nanobiotechnology. 2025 Dec 20. [Abstract]
- J Nanobiotechnology. 2025 Feb 25;23(1):140. [Abstract]
- J Nanobiotechnology. 2025 Mar 6;23(1):175. [Abstract]
- J Nanobiotechnology. 2025 Feb 28;23(1):155. [Abstract]
- J Nanobiotechnology. 2024 Sep 19;22(1):575. [Abstract]
- J Nanobiotechnology. 2024 Aug 14;22(1):486. [Abstract]
- Carbohydr Polym. 2026 Feb 1:373:124618. [Abstract]
- Sci Adv. 2023 Oct 6;9(40):eadi8343. [Abstract]
- Redox Biol. 2026 May:92:104133. [Abstract]
- Redox Biol. 2026 May:92:104102. [Abstract]
- J Control Release. 2020 Jan 28;320:304-313. [Abstract]
- J Hazard Mater. 2024 Dec 2:485:136750. [Abstract]
- Environ Sci Technol. 2023 Dec 5;57(48):20219-20227. [Abstract]
- J Hazard Mater. 2023 Jun 15:452:131262. [Abstract]
- Genome Med. 2025 Nov 4;17(1):138. [Abstract]
- Research (Wash D C). 2025 Jul 22:8:0784. [Abstract]
- MedComm. 2023 Jun 5;4(3):e293. [Abstract]
- J Immunother Cancer. 2026 Mar 11;14(3):e014276. [Abstract]
- Cell Rep Med. 2026 Apr 21;7(4):102691. [Abstract]
- Cell Rep Med. 2025 May 23:102155. [Abstract]
- Pharmacol Res. 2024 Nov 27:107525. [Abstract]
- Mater Today Bio. 2025 Nov 24:35:102606. [Abstract]
- Mater Today Bio. 2025 Nov 28.
- Mater Today Bio. 2025 Mar 21:32:101697. [Abstract]
- Mater Today Bio. 2025 Feb 1:31:101539. [Abstract]
- Mater Today Bio. 2024 Sep 23:29:101261. [Abstract]
- Cancer Lett. 2026 Apr 10:643:218288. [Abstract]
- J Neuroinflammation. 2025 Dec 3;22(1):283. [Abstract]
- J Neuroinflammation. 2025 Nov 26;22(1):280. [Abstract]
- Cancer Lett. 2024 Apr 10:587:216732. [Abstract]
- ISME J. 2025 Aug 13:wraf175. [Abstract]
- ISME J. 2025 Apr 30:wraf084. [Abstract]
- Int J Biol Sci. 2020 Jun 27;16(13):2382-2391. [Abstract]
- Adv Healthc Mater. 2026 Mar 6:e05668. [Abstract]
- Cell Death Dis. 2025 Aug 18;16(1):625. [Abstract]
- Adv Healthc Mater. 2025 Aug 20:e01886. [Abstract]
- Adv Healthc Mater. 2025 Jul 6:e2502562. [Abstract]
- Acta Biomater. 2024 Aug 7:S1742-7061(24)00445-8. [Abstract]
- Biomater Res. 2022 Apr 25;26(1):15. [Abstract]
- Cell Death Dis. 2022 Feb 24;13(2):183. [Abstract]
- Cell Death Dis. 2022 Jan 21;13(1):73. [Abstract]
- Sci China Life Sci. 2024 Dec;67(12):2664-2677. [Abstract]
- NPJ Biofilms Microbiomes. 2025 Apr 15;11(1):59. [Abstract]
- Nano Res. 2026;19(1):94907900.
- Cell Commun Signal. 2025 Feb 7;23(1):68. [Abstract]
- Cell Commun Signal. 2025 Feb 5;23(1):65. [Abstract]
- Cell Commun Signal. 2025 Jan 6;23(1):6. [Abstract]
- J Pharm Anal. 2025 Jul;15(7):101154. [Abstract]
- Cell Commun Signal. 2023 Dec 15;21(1):356. [Abstract]
- Dev Cell. 2025 Jun 23;60(12):1669-1685.e6. [Abstract]
- Int J Biol Macromol. 2026 Jan;339(Pt 2):150110. [Abstract]
- Int J Biol Macromol. 2025 Sep;321(Pt 4):146626. [Abstract]
- Int J Biol Macromol. 2025 Aug;320(Pt 4):145769. [Abstract]
- Int J Biol Macromol. 2025 Apr 9:143030. [Abstract]
- Int J Biol Macromol. 2025 May;306(Pt 3):142024. [Abstract]
- Int J Biol Macromol. 2024 Sep 18:135743. [Abstract]
- Int J Biol Macromol. 2024 Mar;261(Pt 1):129674. [Abstract]
- Int J Biol Macromol. 2024 Mar;260(Pt 1):129455. [Abstract]
- Acta Pharmacol Sin. 2026 Mar 10. [Abstract]
- Cancer Biol Med. 2025 Oct 23:j.issn.2095-3941.2024.0241. [Abstract]
- Acta Pharmacol Sin. 2025 May 20. [Abstract]
- Acta Pharmacol Sin. 2025 Feb;46(2):353-365. [Abstract]
- Acta Pharmacol Sin. 2023 Jun;44(6):1135-1148. [Abstract]
- Acta Pharmacol Sin. 2023 Jan;44(1):71-80. [Abstract]
- Phytomedicine. 2026 Jun:155:158070. [Abstract]
- Phytomedicine. 2026 Apr:153:157985. [Abstract]
- Phytomedicine. 2026 Apr:153:157917. [Abstract]
- Phytomedicine. 2025 Oct 27:148:157481. [Abstract]
- Phytomedicine. 2025 Jun:141:156671. [Abstract]
- Phytomedicine. 2025 Jul:142:156698. [Abstract]
- Phytomedicine. 2024 Aug:131:155776. [Abstract]
- Phytomedicine. 2024 Mar:125:155356. [Abstract]
- Phytomedicine. 2022 Nov:106:154416. [Abstract]
- ACS Appl Mater Interfaces. 2025 Dec 24;17(51):69180-69195. [Abstract]
- Free Radic Biol Med. 2025 Nov 23:243:398-413. [Abstract]
- ACS Appl Mater Interfaces. 2025 Oct 23. [Abstract]
- Free Radic Biol Med. 2025 Sep 11:S0891-5849(25)00976-1. [Abstract]
- ACS Appl Mater Interfaces. 2025 Oct 1;17(39):54608-54622. [Abstract]
- Free Radic Biol Med. 2025 Aug 11:240:238-252. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jul 30;17(30):42637-42657. [Abstract]
- Apoptosis. 2026 Jan 10;31(1):36. [Abstract]
- Food Res Int. 2025 Dec;221(Pt 4):117582. [Abstract]
- Food Res Int. 2022 May:155:111003. [Abstract]
- Mater Des. 2024 Sep.
- J Headache Pain. 2024 Jan 5;25(1):3. [Abstract]
- J Orthop Translat. 2025 Aug 1.
- Br J Pharmacol. 2025 Dec 30. [Abstract]
- Br J Pharmacol. 2024 Oct;181(19):3760-3778. [Abstract]
- Sens Actuators B Chem. 15 December 2022, 132707.
- Brain Behav Immun. 2026 Jan 26:134:106472. [Abstract]
- Brain Behav Immun. 2025 Jul:127:126-146. [Abstract]
- Mucosal Immunol. 2024 Jul 1:S1933-0219(24)00065-5. [Abstract]
- J Transl Med. 2025 Oct 14;23(1):1096. [Abstract]
- Biomed Pharmacother. 2025 Mar 25:186:118008. [Abstract]
- Biomed Pharmacother. 2024 Oct 31:181:117659. [Abstract]
- J Transl Med. 2024 Sep 27;22(1):871. [Abstract]
- Biomed Pharmacother. 2024 Jun 21:177:117006. [Abstract]
- Biomed Pharmacother. 2024 Apr:173:116425. [Abstract]
- Biomed Pharmacother. 2022 Jul;151:113098. [Abstract]
- Redox Rep. 2026 Dec;31(1):2627096. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2022 Apr 2;14(1):75-99. [Abstract]
- Chin Med J (Engl). 2025 Dec 19. [Abstract]
- Stem Cell Res Ther. 2025 May 1;16(1):222. [Abstract]
- Stem Cell Res Ther. 2025 Feb 21;16(1):80. [Abstract]
- Environ Pollut. 2023 Jan 15:317:120730. [Abstract]
- Journal of Future Foods. 2025 Sep 18.
- Cell Death Discov. 2025 Jul 1;11(1):290. [Abstract]
- Cell Death Discov. 2025 Jul 24;11(1):339. [Abstract]
- Cell Death Discov. 2025 Jul 22;11(1):337. [Abstract]
- Cell Death Discov. 2025 Feb 20;11(1):69. [Abstract]
- Cell Death Discov. 2023 Dec 5;9(1):440. [Abstract]
- Cell Death Discov. 2021 May 8;7(1):96. [Abstract]
- Cell Rep. 2025 Sep 26;44(10):116350. [Abstract]
- Clin Transl Med. 2024 Mar;14(3):e1623. [Abstract]
- Neural Regen Res. 2025 Oct 30. [Abstract]
- Anal Chem. 2025 Jul 22;97(28):14943-14955. [Abstract]
- Neural Regen Res. 2024 Oct 1;19(10):2259-2269. [Abstract]
- Neural Regen Res. 2023 Aug;18(8):1802-1808. [Abstract]
- Int J Nanomedicine. 2026 Mar 25:21:584361. [Abstract]
- Int J Nanomedicine. 2025 Oct 1:20:12009-12018. [Abstract]
- Int J Nanomedicine. 2024 Dec 9:19:13235-13251. [Abstract]
- Int J Nanomedicine. 2024 Oct 5:19:10145-10163. [Abstract]
- Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):440-452. [Abstract]
- Elife. 2022 May 4;11:e76707. [Abstract]
- Phytother Res. 2021 Jun;35(6):3406-3417. [Abstract]
- J Agric Food Chem. 2024 May 16. [Abstract]
- J Agric Food Chem. 2024 Apr 17;72(15):8460-8475. [Abstract]
- Ecotoxicol Environ Saf. 2023 Jan 1:249:114359. [Abstract]
- Biomater Adv. 2026 Jul:184:214832. [Abstract]
- Biomater Adv. 2026 Jun:183:214767. [Abstract]
- Front Immunol. 2022 Jun 10;13:859806. [Abstract]
- Front Immunol. 2021 Jul 7:12:688674. [Abstract]
- Int J Mol Med. 2026 May;57(5):115. [Abstract]
- Neurosci Bull. 2025 Dec 27. [Abstract]
- Int J Mol Med. 2021 Jan;47(1):137-150. [Abstract]
- Biomater Sci. 2023 Mar 28;11(7):2445-2460. [Abstract]
- Chin Med. 2022 Jan 5;17(1):7. [Abstract]
- Cell Prolif. 2025 Dec 30:e70160. [Abstract]
- Biochem Pharmacol. 2025 Dec 17:245:117657. [Abstract]
- Biochem Pharmacol. 2025 Sep 20;242(Pt 3):117352. [Abstract]
- Biochem Pharmacol. 2025 Jul 17:117177. [Abstract]
- Cell Prolif. 2025 Jul 4:e70085. [Abstract]
- Biochem Pharmacol. 2025 Jun:236:116870. [Abstract]
- Biochem Pharmacol. 2024 May 24:116314. [Abstract]
- Biochem Pharmacol. 2023 Jul:213:115599. [Abstract]
- Biochem Pharmacol. 2022 Jan:195:114863. [Abstract]
- ACS Appl Nano Mater. 2025 Jun 10;8(24).
- Am J Chin Med. 2025;53(2):501-522. [Abstract]
- Am J Chin Med. 2024;52(2):471-492. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- J Ethnopharmacol. 2026 Jun 12:364:121483. [Abstract]
- J Enzyme Inhib Med Chem. 2026 Dec;41(1):2631869. [Abstract]
- J Ethnopharmacol. 2026 Apr 6:360:121209. [Abstract]
- Chem Biol Interact. 2026 Jan 25:424:111862. [Abstract]
- J Ethnopharmacol. 2026 Mar 25:359:121046. [Abstract]
- J Ethnopharmacol. 2026 Feb 10:356:120859. [Abstract]
- Biomacromolecules. 2026 Jan 12;27(1):164-178. [Abstract]
- Food Funct. 2025 Oct 27. [Abstract]
- J Ethnopharmacol. 2025 Sep 5:120547. [Abstract]
- J Ethnopharmacol. 2025 Sep 22;355(Pt A):120628. [Abstract]
- J Ethnopharmacol. 2025 Jul 30;353(Pt A):120346. [Abstract]
- J Ethnopharmacol. 2025 Jul 17;353(Pt A):120310. [Abstract]
- Inflamm Res. 2025 May 24;74(1):85. [Abstract]
- J Ethnopharmacol. 2025 Jan 8:119342. [Abstract]
- J Ethnopharmacol. 2025 Jan 30;337(Pt 2):118856. [Abstract]
- J Ethnopharmacol. 2024 Oct 16;337(Pt 3):118937. [Abstract]
- Food Funct. 2024 Nov 11;15(22):11236-11251. [Abstract]
- J Ethnopharmacol. 2024 Jul 9:118541. [Abstract]
- J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117214. [Abstract]
- Food Funct. 2022 Jan 24;13(2):753-768. [Abstract]
- Cells. 2025 Sep 16;14(18):1452. [Abstract]
- Commun Biol. 2025 Dec 17;8(1):1813. [Abstract]
- Commun Biol. 2025 Jul 5;8(1):1009. [Abstract]
- Drug Des Devel Ther. 2025 Jul 30:19:6573-6585. [Abstract]
- Drug Des Devel Ther. 2025 Jun 20:19:5293-5310. [Abstract]
- Drug Des Devel Ther. 2024 Dec 27:18:6313-6329. [Abstract]
- Foods. 2024 Jan 7;13(2):195. [Abstract]
- Life Sci. 2024 Jan 1:336:122326. [Abstract]
- Journal of Pharmaceutical Investigation. 2021 Mar 31.
- Nutrients. 2026 Mar 25;18(7):1048. [Abstract]
- Biofactors. 2026 Jan-Feb;52(1):e70079. [Abstract]
- Inflammation. 2026 Jan 16;49(1):51. [Abstract]
- Inflammation. 2025 Feb 4. [Abstract]
- Inflammation. 2025 Apr;48(2):590-606. [Abstract]
- Cancer Gene Ther. 2024 May;31(5):755-765. [Abstract]
- CNS Neurosci Ther. 2024 Jan;30(1):e14566. [Abstract]
- Respir Res. 2022 Dec 28;23(1):380. [Abstract]
- Int J Mol Sci. 2026 Jun 9;27(12):5229. [Abstract]
- PLoS Pathog. 2026 Feb 25;22(2):e1013874. [Abstract]
- Int J Mol Sci. 2025 Oct 30;26(21):10556. [Abstract]
- Int J Mol Sci. 2025 Oct 6;26(19):9718. [Abstract]
- J Nutr Biochem. 2025 Apr 28:109939. [Abstract]
- Int J Mol Sci. 2025 Apr 11;26(8):3603. [Abstract]
- Biol Direct. 2025 Mar 24;20(1):35. [Abstract]
- PLoS Pathog. 2025 Mar 11;21(3):e1012985. [Abstract]
- Int J Mol Sci. 2024 Nov 14;25(22):12260. [Abstract]
- PLoS Pathog. 2024 Jul 22;20(7):e1012398. [Abstract]
- Int J Mol Sci. 2022 Sep 24;23(19):11279. [Abstract]
- Int J Mol Sci. 2020 Dec 23;22(1):60. [Abstract]
- Pharmaceuticals (Basel). 2026 Mar 11;19(3):452. [Abstract]
- Pharmaceuticals (Basel). 2023 Jun 15;16(6):885. [Abstract]
- Pharm Biol. 2022 Dec;60(1):1949-1959. [Abstract]
- Front Pharmacol. 2021 Apr 15:12:663325. [Abstract]
- Eur J Pharmacol. 2026 Apr 10:1020:178777. [Abstract]
- ACS Appl Bio Mater. 2026 Mar 2;9(5):2574-2590. [Abstract]
- Int Immunopharmacol. 2026 Apr 1:174:116322. [Abstract]
- Int Immunopharmacol. 2025 Dec 11:169:116009. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 1):115802. [Abstract]
- Int Immunopharmacol. 2025 Dec 3:166:115644. [Abstract]
- Int Immunopharmacol. 2025 Sep 5:165:115437. [Abstract]
- Int Immunopharmacol. 2025 Apr 29:157:114743. [Abstract]
- Int Immunopharmacol. 2025 Apr 10:155:114632. [Abstract]
- Int Immunopharmacol. 2025 Apr 9:155:114588. [Abstract]
- Int Immunopharmacol. 2025 Apr 16:152:114405. [Abstract]
- Int Immunopharmacol. 2025 Jan 16:148:114048. [Abstract]
- Int Immunopharmacol. 2025 Jan 18:148:114057. [Abstract]
- Int Immunopharmacol. 2024 Sep 23;142(Pt B):113092. [Abstract]
- Int Immunopharmacol. 2024 Oct 16;143(Pt 2):113328. [Abstract]
- Int Immunopharmacol.2024 May 22:135:112277. [Abstract]
- Int Immunopharmacol. 2024 Feb 15:128:111463. [Abstract]
- Int Immunopharmacol. 2023 Oct:123:110763. [Abstract]
- Int Immunopharmacol. 2023 Jul:120:110240. [Abstract]
- Int Immunopharmacol. 2023 Mar:116:109747. [Abstract]
- Int Immunopharmacol. 2020 Nov;88:106965. [Abstract]
- Molecules. 2026 Mar 27;31(7):1105. [Abstract]
- Arthritis Res Ther. 2025 Nov 18;27(1):216. [Abstract]
- Molecules. 2024 Oct 31;29(21):5160. [Abstract]
- Molecules. 2023 Oct 16;28(20):7116. [Abstract]
- Molecules. 2023 Mar 23;28(7):2903. [Abstract]
- J Med Virol. 2020 Dec;92(12):3057-3066. [Abstract]
- Genes Immun. 2025 Aug;26(4):365-375. [Abstract]
- Gene Ther. 2022 Jun;29(6):379-389. [Abstract]
- Probiotics Antimicrob Proteins. 2025 Jun 6. [Abstract]
- Immunotargets Ther. 2024 Dec 14:13:775-788. [Abstract]
- Mol Neurobiol. 2026 Jan 23;63(1):390. [Abstract]
- Mol Neurobiol. 2025 Dec 1;63(1):221. [Abstract]
- Eur J Nutr. 2022 Aug;61(5):2749-2759. [Abstract]
- Front Cell Dev Biol. 2021 Apr 15;9:665869. [Abstract]
- Drug Dev Res. 2026 Feb;87(1):e70223. [Abstract]
- Mediators Inflamm. 2026 Jan 22:2026:5595023. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Sep 19;1872(1):168053. [Abstract]
- FASEB J. 2025 Aug 15;39(15):e70845. [Abstract]
- Exp Neurol. 2025 Nov:393:115371. [Abstract]
- J Food Biochem. 2025 Jul 16.
- J Food Biochem. 2025 Jun 13.
- J Cell Mol Med. 2025 Jan;29(2):e70338. [Abstract]
- J Cell Mol Med. 2024 Nov;28(22):e70214. [Abstract]
- Exp Neurol. 2024 Dec:382:114987. [Abstract]
- Mol Nutr Food Res. 2024 Aug 1:e2400307. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Jun 11;1870(7):167281. [Abstract]
- J Clin Transl Hepatol. 2024 May 28;12(5):481-495. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Mar 31;1870(5):167142. [Abstract]
- FASEB J. 2024 Mar 31;38(6):e23551. [Abstract]
- Exp Neurol. 2024 May:375:114738. [Abstract]
- J Cell Mol Med. 2024 Jan;28(1):e18037. [Abstract]
- J Cell Mol Med. 2020 Oct;24(20):11742-11754. [Abstract]
- J Inflamm Res. 2026 Mar 3:19:551466. [Abstract]
- J Inflamm Res. 2025 Oct 1:18:13575-13592. [Abstract]
- J Inflamm Res. 2025 Jun 3:18:7167-7181. [Abstract]
- iScience. 2024 May 3;27(6):109870. [Abstract]
- iScience. 2024 Apr 5;27(6):109667. [Abstract]
- J Inflamm Res. 2024 Apr 9:17:2147-2158. [Abstract]
- iScience. 2023 Sep 24;26(10):108043. [Abstract]
- Toxics. 2022 May 27;10(6):285. [Abstract]
- J Inflamm Res. 2022 Jan 7;15:127-140. [Abstract]
- J Biol Chem. 2026 Jan 20:111182. [Abstract]
- Sci Rep. 2026 Jan 3;16(1):3332. [Abstract]
- Sci Rep. 2025 Dec 29;15(1):44695. [Abstract]
- Sci Rep. 2025 Oct 31;15(1):38137. [Abstract]
- J Biomed Mater Res A. 2025 Dec;113(12):e70006. [Abstract]
- J Cell Commun Signal. 2025 Sep 4;19(3):e70044. [Abstract]
- Sci Rep. 2025 Aug 1;15(1):28125. [Abstract]
- Fish Shellfish Immunol. 2025 Jun 24:110520. [Abstract]
- Sci Rep. 2025 Mar 22;15(1):9965. [Abstract]
- Sci Rep. 2024 Oct 14;14(1):24054. [Abstract]
- Sci Rep. 2024 Aug 5;14(1):18094. [Abstract]
- J Drug Target. 2024 Jun;32(5):570-584. [Abstract]
- Biomedicines. 2023 Jun 1;11(6):1615. [Abstract]
- Biomedicines. 2023 Jun 4;11(6):1637. [Abstract]
- Aging (Albany NY). 2021 Sep 28;13(18):22588-22610. [Abstract]
- Aging (Albany NY). 2021 Feb 11;13(4):5650-5673. [Abstract]
- Aging (Albany NY). 2021 Mar 10;13(6):8588-8598. [Abstract]
- Mol Divers. 2026 May 8. [Abstract]
- Food Sci Nutr. 2026 Jan 7;14(1):e71429. [Abstract]
- ACS Infect Dis. 2025 Sep 22. [Abstract]
- J Periodontol. 2024 Mar;95(3):268-280. [Abstract]
- Neurochem Res. 2023 Jan;48(1):172-187. [Abstract]
- J Periodontol. 2022 Nov;93(11):1738-1751. [Abstract]
- Aquac Rep. 2026 Mar 6.
- Cell Signal. 2026 May:141:112385. [Abstract]
- Cell Signal. 2025 May 27:134:111905. [Abstract]
- Cytokine. 2024 Oct 31:184:156796. [Abstract]
- Int Dent J. 2024 May 27:S0020-6539(24)00125-4. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2024 Mar 22;1871(4):119712. [Abstract]
- Brain Res Bull. 2022 Sep:187:169-180. [Abstract]
- Biol Trace Elem Res. 2025 Apr;203(4):1898-1908. [Abstract]
- J Proteome Res. 2023 Nov 3;22(11):3559-3569. [Abstract]
- Exp Cell Res. 2025 Nov 25;454(2):114842. [Abstract]
- Vet Res. 2025 Oct 16;56(1):199. [Abstract]
- Clin Exp Med. 2025 Aug 21;25(1):297. [Abstract]
- Food Chem Toxicol. 2025 Apr 25:115488. [Abstract]
- Parasit Vectors. 2023 Apr 24;16(1):139. [Abstract]
- Viruses. 2022 Feb 15;14(2):394. [Abstract]
- Mol Med Rep. 2021 Sep;24(3):672. [Abstract]
- J Gastroenterol Hepatol. 2026 Mar 19. [Abstract]
- Toxicol Appl Pharmacol. 2025 Dec 30:507:117702. [Abstract]
- Cell Cycle. 2025 Jun 5:1-17. [Abstract]
- Eur J Med Res. 2025 Jun 21;30(1):504. [Abstract]
- Toxicol Appl Pharmacol. 2025 May 29:117416. [Abstract]
- Eur J Med Res. 2025 Jan 7;30(1):12. [Abstract]
- Vaccines. 2025 Jan 13;13(1):64. [Abstract]
- Acta Biochim Biophys Sin (Shanghai). 2024 Nov 1;57(5):727-737. [Abstract]
- BMC Biotechnol. 2024 Jun 7;24(1):40. [Abstract]
- BMC Complement Med Ther. 2023 Oct 10;23(1):358. [Abstract]
- Acta Biochim Biophys Sin. 2021 May 21;53(6):748-757. [Abstract]
- Neurotox Res. 2026 Mar 19;44(2):12. [Abstract]
- Appl Biochem Biotechnol. 2025 Oct 28. [Abstract]
- Hum Exp Toxicol. 2026 Jan-Dec:45:9603271251411659. [Abstract]
- Pathol Res Pract. 2025 Oct 17;276:156273.
- J Pharm Pharmacol. 2025 Aug 22:rgaf060. [Abstract]
- Hum Exp Toxicol. 2025 Jan-Dec:44:9603271251324582. [Abstract]
- Environ Toxicol. 2024 Jan;39(1):357-366. [Abstract]
- Environ Toxicol. 2023 Nov;38(11):2585-2594. [Abstract]
- Nitric Oxide. 2022 Dec 1:129:41-52. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 23. [Abstract]
- Hum Cell. 2025 Sep 30;38(6):168. [Abstract]
- J Pharm Biomed Anal. 2025 Sep 30:267:117174. [Abstract]
- Kaohsiung J Med Sci. 2025 Sep;41(9):e70052. [Abstract]
- J Appl Biomater Funct Mater. 2024 Jan-Dec:22:22808000241289022. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8745-8758. [Abstract]
- Int J Chron Obstruct Pulmon Dis. 2024 Apr 18:19:957-967. [Abstract]
- Kaohsiung J Med Sci. 2022 Dec;38(12):1168-1177. [Abstract]
- Kaohsiung J Med Sci. 2021 Oct;37(10):883-893. [Abstract]
- Cell Biol Int. 2021 Aug;45(8):1743-1756. [Abstract]
- Ren Fail. 2025 Dec;47(1):2593719. [Abstract]
- Mol Immunol. 2024 Dec 25:177:73-84. [Abstract]
- Arch Biochem Biophys. 2024 Jul 17:110102. [Abstract]
- Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. [Abstract]
- Ren Fail. 2024 Dec;46(1):2329257. [Abstract]
- Mol Immunol. 2024 Mar:167:25-33. [Abstract]
- Mol Immunol. 2022 Feb:142:63-75. [Abstract]
- Mol Immunol. 2021 Sep:137:155-162. [Abstract]
- Toxicol Lett. 2025 Dec 9:415:111802. [Abstract]
- Oral Dis. 2025 Apr 21. [Abstract]
- J Biochem Mol Toxicol. 2025 Aug;39(8):e70434. [Abstract]
- Mol Pain. 2025 Aug 18:17448069251374281. [Abstract]
- J Orthop Surg Res. 2024 Dec 2;19(1):814. [Abstract]
- Infect Immun. 2024 Aug 29:e0017224. [Abstract]
- Cell Biochem Funct. 2025 Dec;43(12):e70152. [Abstract]
- Immun Inflamm Dis. 2025 Aug;13(8):e70243. [Abstract]
- Vet Microbiol. 2025 Aug:307:110628. [Abstract]
- Toxicol In Vitro. 2023 Apr:88:105552. [Abstract]
- PLoS One. 2026 Jan 21;21(1):e0340291. [Abstract]
- Brain Res. 2025 Dec 17:1873:150116. [Abstract]
- Fitoterapia. 2025 Sep 13:187:106868. [Abstract]
- Brain Res. 2025 May 15:1855:149560. [Abstract]
- Brain Res. 2024 Jul 6:149115. [Abstract]
- Brain Res. 2024 Sep 1:1838:148975. [Abstract]
- Mol Biotechnol. 2025 Oct 30. [Abstract]
- Hereditas. 2025 Mar 22;162(1):44. [Abstract]
- Cell Biochem Biophys. 2025 Jun;83(2):1565-1573. [Abstract]
- Clin Exp Pharmacol Physiol. 2023 Mar;50(3):218-227. [Abstract]
- Theriogenology. 2022 Nov:193:68-76. [Abstract]
- Chin J Integr Med. 2022 Feb;28(2):153-161. [Abstract]
- Gene. 2025 Oct 20:970:149785. [Abstract]
- PeerJ. 2024 Nov 13:12:e18448. [Abstract]
- PeerJ. 2024 Apr 18:12:e17106. [Abstract]
- PeerJ. 2023 Mar 28:11:e15122. [Abstract]
- Immunol Invest. 2023 Feb;52(2):178-193. [Abstract]
- Immunobiology. 2025 Mar 12;230(3):152891. [Abstract]
- Exp Ther Med. 2023 Mar 14;25(4):187. [Abstract]
- Behav Brain Res. 2022 Apr 29:424:113813. [Abstract]
- Exp Ther Med. 2021 Dec;22(6):1389. [Abstract]
- J Mol Histol. 2026 Jan 5;57(1):17. [Abstract]
- Hum Immunol. 2025 Aug 19;86(5):111566. [Abstract]
- Biochem Biophys Res Commun. 2025 May 28:775:152112. [Abstract]
- Biochem Biophys Res Commun. 2025 May 28:775:152110. [Abstract]
- J Mol Histol. 2024 Nov 29;56(1):7. [Abstract]
- Biomol Biomed. 2025 Mar 7;25(4):857-868. [Abstract]
- Biochem Biophys Res Commun. 2023 Jul 23:666:115-121. [Abstract]
- Korean J Physiol Pharmacol. 2021 Sep 1;25(5):395-401. [Abstract]
- Kidney Blood Press Res. 2026 Mar 17:1-18. [Abstract]
- Hypertens Pregnancy. 2026 Dec 31;45(1):2609374. [Abstract]
- Arch Oral Biol. 2026 Mar:183:106496. [Abstract]
- Brain Mechanisms. 2025 Nov 21.
- Eur J Histochem. 2025 Apr 7;69(2). [Abstract]
- Arch Oral Biol. 2025 Jul:175:106253. [Abstract]
- Arch Oral Biol. 2024 Jul:163:105974. [Abstract]
- COPD. 2023 Dec;20(1):348-356. [Abstract]
- Arch Oral Biol. 2021 Nov:131:105269. [Abstract]
- J Gastrointest Oncol. 2025 Apr 30;16(2):599-614. [Abstract]
- Neurosci Lett. 2023 Feb 28:798:137058. [Abstract]
- Neurosci Lett. 2022 Jan 18:768:136374. [Abstract]
- J Herb Med. 2025 Aug 20.
- Drug Chem Toxicol. 2024 Dec 29:1-10. [Abstract]
- Nephrology (Carlton). 2024 Aug;29(8):482-494. [Abstract]
- Res Vet Sci. 2022 Dec:149:1-10. [Abstract]
- Cytotechnology. 2026 Apr;78(2):63. [Abstract]
- Cytotechnology. 2026 Feb;78(1):21. [Abstract]
- Neuroreport. 2025 Dec 10;36(18):1047-1054. [Abstract]
- Growth Factors. 2025 Jul 22:1-11. [Abstract]
- In Vitro Cell Dev Biol Anim. 2025 Jun;61(6):635-643. [Abstract]
- Cytotechnology. 2025 Apr;77(2):66. [Abstract]
- Exp Brain Res. 2025 Dec 16;244(1):13. [Abstract]
- Respir Physiol Neurobiol. 2021 Oct:292:103711. [Abstract]
- J Int Med Res. 2025 Nov;53(11):3000605251396755. [Abstract]
- Neurol Res. 2025 Nov 7:1-21. [Abstract]
- Neurol Res. 2025 Nov 11:1-13. [Abstract]
- J Toxicol Sci. 2025;50(10):555-567. [Abstract]
- J Vet Sci. 2023 Sep;24(5):e72. [Abstract]
- Mol Cell Toxicol. 2025 Dec 10.
- Mol Cell Toxicol. 2025 May 15.
- Vet Immunol Immunopathol. 2024 Nov:277:110839. [Abstract]
- Transpl Immunol. 2023 Feb:76:101681. [Abstract]
- J Asian Nat Prod Res. 2023 Feb;25(2):147-155. [Abstract]
- Exp Anim. 2023 Feb 21;72(1):77-87. [Abstract]
- Curr Proteomics. 2026 Mar 25.
- Res Sq. 2026 Feb 19.
- Patent. US20260000715A1.
- bioRxiv. 2026 Jan 29.
- SSRN. 2025 Dec 17.
- SSRN. 2025 Dec 31.
- SSRN. 2025 Nov 16.
- bioRxiv. 2025 Oct 26.
- iMetaMed. 2025 Oct 21.
- Res Sq. 2025 Oct 14.
- SSRN. 2025 Sep 11.
- SSRN. 2025 Aug 7.
- Res Sq. 2025 Jul 17.
- Res Sq. 2025 Jul 17.
- SSRN. 2025 Jul 2.
- Res Sq. 2025 Jul 20.
- Original Article. 2025.
- SSRN. 2025 Apr 10.
- Res Sq. 2025 Apr 22.
- bioRxiv. 2025 February 27.
- Journal of Experimental and Clinical Anatomy. 2024 Dec 31.
- Res Sq. 2024 Sep 30.
- Res Sq. 2024 Nov 04.
- Research Square Preprint. 2024 Sep 10.
- Res Sq. 2024 Sep 08.
- Res Sq. 2024 Sep 08.
- Preprints. 2024 Aug 27.
- Research Square Preprint. 2024 May 3.
- SSRN. 2024 Apr 1.
- SSRN. 2024 Jan 9.
- Research Square Preprint. 2024 Jan 24.
- Preprints. 2023 Dec 12.
- Research Square Preprint. 2023 Dec 12.
- Research Square Preprint. 2023 Oct 10.
- Research Square Preprint. 2023 Sep 18.
- Research Square Preprint. 2023 Aug 30.
- Research Square Preprint. 2023 Sep 8.
- Research Square Preprint. 2023 Jul 28.
- Research Square Print. 2023 Feb 8.
- J Pers Med. 2023 Jan 11;13(1):146. [Abstract]
- Research Square Print. December 19th, 2022.
- Research Square Print. October 12th, 2022.
- Contrast Media Mol Imaging. 2022 Aug 18:2022:3517020. [Abstract]
- Evid Based Complement Alternat Med. 2022 Jun 17:2022:1046712. [Abstract]
- bioRxiv. January 04, 2022.
- Research Square Preprint. 2021 Oct.
- Research Square Preprint. 2021 Jul.
- Research Square Preprint. 2021 Jun.
- Research Square Preprint. 2020 Dec.
-
WB
-
IF
-
RT-PCR
-
WB
-
RT-PCR
Biological Activity
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
|
TLR4 |
Note:
1. Concentration and Time: Please do not rely solely on a single article to determine experimental conditions. It is recommended to review relevant literature based on the cell line and type of LPS before formal experiments, as the required induction time or optimal concentration for different inflammatory factors to reach their peak may vary. It is advisable to set concentration and time gradients to identify the optimal experimental scheme.
2. Detection Indicators: LPS does not necessarily induce cell death; therefore, it is not appropriate to determine the LPS modeling concentration and time solely by assessing cell viability. It is recommended to measure the expression or secretion of inflammatory factors.
3. Solvent Selection: Literature indicates that certain concentrations of DMSO can significantly inhibit LPS-induced inflammatory responses. In cellular experiments, it is recommended to prepare stock solutions using sterile water, followed by dilution with culture medium.
4. Container Selection: Due to the adsorption characteristics of LPS, it can bind to plastics and certain types of glass (especially at concentrations <0.1 mg/mL). The adsorption effect is relatively small when LPS concentrations exceed 1 mg/mL. Additionally, LPS tends to form micelles in solution. Therefore, when dissolving the powder, it is recommended to prepare concentrations of ≥2 mg/mL, and to vortex thoroughly for more than 10 minutes. If necessary, ultrasonic assistance may be used. For storage, please use silanized containers or low-adhesion centrifuge tubes. If glass containers are used, ensure to mix thoroughly for at least 30 minutes prior to use to re-dissolve any LPS adsorbed to the wall of the container.
5. Concentration Units: LPS does not have a uniform molecular weight because its molecules exhibit heterogeneity and aggregation. The molecular weight of naturally sourced LPS typically ranges from 10-100 kDa or even higher. Common dosing concentrations for LPS found in the literature are in terms of mass concentration, such as ng/mL and μg/mL, so it is sufficient to prepare solutions directly in mass concentration during experiments.
6. Filtration Sterilization: After dissolving LPS powder in water, saline, or PBS, the solution may appear turbid or colloidal, and in some cases, a microsphere distribution with diameters around 20-30 nm may be observed. When sterilizing by filtration, do not filter the stock solution directly. It is recommended to dilute to working solution first and then filter sterilize through a 0.22 μm filter membrane.
7. Differences Among Different Strain LPS: LPS of different catalog numbers comes from various bacterial strains, corresponding to different structural features such as lipid A, core polysaccharides, and O-antigens, which in turn affect the intensity of inflammation induction and TLR4-mediated signaling bias. Commonly referenced LPS catalog numbers for in vitro or in vivo inflammation model construction include HY-D1056 and HY-D1056A1. Moreover, in specific research contexts, specialized sources of LPS related to the studied bacterial strains may also be used. For example, HY-D1056D (from Porphyromonas gingivalis) is used in periodontal studies, while HY-D1056B3 (from Klebsiella pneumoniae) is relevant in pneumonia-related research. When selecting LPS, considerations should include the purpose of the experiment, sensitivity of the cell line, and other factors.
LPS is the major toxic component of Gram-negative bacteria, capable of activating pathogen-associated molecular patterns (PAMP) of the immune system and inducing cellular secretion of migrasomes. LPS can be recognized by TLR4, activating the innate immune system, followed by the promotion of NF-κB activation and the production of pro-inflammatory cytokines. It is commonly used in experiments involving the stimulation, activation, and differentiation of immune cells.
Different bacterial species express LPS with varying structures and biological activities. LPS generally exists in two configurations: R (rough) type and S (smooth) type. S-type LPS contains a typical three-part structure: O-antigen (O-antigen) (serum-specific polysaccharides composed of repeating oligosaccharide units), core oligosaccharide (core) (non-repeating C9-type oligosaccharides), and lipid A (Lipid A) (the toxic component of LPS). The R type lacks the O-antigen and expresses rough-type LPS. The absence of O-antigen can affect the process of immune cell recognition of LPS.
The LPS expressed by the E. coli 055:B5 strain serves as a prototype endotoxin frequently used as an endotoxin standard in LAL assays. Lipopolysaccharides, from E. coli O55:B5 exhibit high pyrogenicity and are commonly used for in vitro cell activation. Lipopolysaccharides, from E. coli O55:B5 induce the secretion of pro-inflammatory cytokines in mouse macrophages[1].
Administration: 0.1-10 μg/mL • 1-24 h
(2) Stimulating cells with LPS does not necessarily lead to cell death. Therefore, it is not appropriate to determine the concentration and time of LPS for establishing the model merely by detecting cell viability. It is recommended to detect the expression and secretion of multiple inflammatory factors.
(3) During the process of stimulating cells with LPS, the morphological changes of cells should be observed regularly. An excessively high concentration may cause cytotoxicity, while an excessively low concentration may fail to effectively damage the cells.
(4) A certain concentration of DMSO can significantly inhibit the inflammatory response induced by LPS. It is recommended to dissolve LPS in PBS or ddH2O.
(5) In the research on the construction of in vitro inflammatory models, Lipopolysaccharides, from E. coli O55:B5 (HY-D1056) and Lipopolysaccharides, from E. coli O111:B4 (HY-D1056A1) are the most widely used LPS, and they are highly recommended!
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female and male CD1 mice[3]
-
Dosage:1.5mg/kg
-
Administration:Intraperitoneal injection, once
-
Result:Induced sickness behavior in all mice, but adult mice displayed more sickness than pubertal mice and adult males remained sick for a longer period of time than adult females.
Caused a decrease in body temperature for all mice, but this decrease was greatest in adult males.
Increased pro- and anti-inflammatory cytokines at various levels in pubertal and adult male and female mice, resulted in age and sex differences in cytokine concentrations following immune challenge.
Only adult males and females treated with LPS displayed significantly more IL-6 than their saline controls, and pubertal males and females and adult females displayed significantly more IL-10 than their saline controls.
All the mice displayed significantly more IL-12 and TNF-α than their saline controls.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Lipopolysaccharides (1.5 mg/kg; i.p.; once) induces sickness and hypothermia in mice, and induces a greater and more prolonged sickness response in adult male mice[3].
Guidelines for Establishing In Vivo Animal Models with LPS
| Animal Models | Recommended LPS Types | Reference Doses and Management Methods (Taking Mice as an Example) | Recommended Detection Indicators |
| Sepsis (Shock) Model [PMID: 26440998; 27127234; 19529910] | LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056) LPS, from E. coli O127:B8 (HY-D1056A2) |
2.5-10 mg/kg; Intraperitoneal injection |
Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA detection of Serum/Plasma). Histopathological Evaluation: HE staining of the kidney, glomerular cell proliferation, epithelial cell degeneration and necrosis, interstitial inflammatory cell infiltration, etc. Others: Serum Scr, BUN (markers of renal filtration function). |
| Cardiac Dysfunction/Myocarditis Model [PMID: 32896106; 36593471] | LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056) |
10 mg/kg; Intraperitoneal injection |
Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA detection of Serum/Plasma). Histopathological Evaluation: HE staining of the heart, disordered arrangement of myocardial fibers, destruction of myocardial tissue, unclear contour, myocardial dissolution, interstitial edema, congestion, inflammatory cell infiltration, etc. Others: Echocardiographic detection of dysfunction. |
| Acute Lung Injury Model [PMID: 31595149; 26888116; 20975550] | LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056) LPS, from Klebsiella pneumonia (HY-D1056B3) |
0.2-15 mg/kg; Intratracheal administration |
Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA/qPCR detection of BALF/lung tissue). Histopathological Evaluation: HE staining of the Lung, leukocyte infiltration in alveoli, thickening of alveolar walls, plaque hemorrhage and interstitial edema, etc. Others: Lung dry/wet ratio (D/W ratio). |
| Acute Liver Injury Model [PMID: 27127234; 36849063] | LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056) |
5-50 μg/kg + D-GalN (200-400 mg/kg); Intraperitoneal injection |
Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA/qPCR detection of serum/liver tissue). Histopathological Evaluation: HE staining of the liver, liver structural disorder, hemorrhagic plaques, inflammatory cell infiltration, etc. Others: Serum ALT, AST (markers of liver injury). |
| Periodontitis Model [PMID: 23167849; 27987467] | LPS, from P. gingivalis (HY-D1056D) LPS, from E. coli O55:B5 (HY-D1056) |
4-10 μg; 2-4 times; Oral periodontal tissue injection |
Assessment of Inflammatory Mediators: iNOS, COX-2, TNF-α, IL-6, etc. (qPCR detection of gingival tissue). Histopathological Evaluation: HE staining of gingival/alveolar bone tissue, Inflammatory cells infiltrate, and collagen fiber bundles are loosely distributed near the tissue-root interface. Others: The number of immune cells in gingival tissue (flow cytometry). |
| Encephalitis Model [PMID: 35858866; PMID: 36240654] | LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from P. gingivalis (HY-D1056D) |
3-5 mg/kg; Intraperitoneal injection |
Assessment of Inflammatory Mediators: IL-1β, IL-6, TNF-α, etc. (qPCR/WB detection of brain/hippocampus tissue). Immunofluorescence Detection: IBA-1 (Microglia marker); GFAP (Astrocyte marker); Siglec-E, etc. |
| Depression Model [PMID: 31327964; 38677623] | LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056) |
5-10 mg/kg; Intraperitoneal injection |
Assessment of Inflammatory Mediators: IL-1β, NLRP3, Caspase-1, etc. (qPCR/WB detection of hippocampus/cortex); IL-6, IL-1β, TNF-α, etc. (ELISA detection of hippocampus/cortex/serum). Immunofluorescence Detection: IBA-1, GFAP, etc. Behavioral Tests/Detection: Tail suspension experiments and forced swimming experiments, etc., has a longer time of immobility and a shortened latency period of immobility. |
| Parkinson's Model [PMID: 35065246; 30455692] | LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from P. gingivalis (HY-D1056D) |
2-5 μg; Black matter injection |
Assessment of Inflammatory Mediators: iNOS, COX-2, etc. ( WB detection of substantia nigra); TNF-α, IL-1β, IL-6, etc. (ELISA/qPCR detection of substantia nigra). Immunofluorescence Assay/Detection: IBA-1, GFAP, etc. Behavioral Tests/Detection: Rotational behavior test, significantly increased number of rotations; Open field test, bradykinesia, reduced exploratory drive in novel environment, preference for peripheral zone activity; Rotarod test, shortened retention time, premature fall latency. Others: Cx43, Tyrosine hydroxylase (WB detection of substantia nigra). |